Molecular Mechanisms of Transformation by Epstein-Barr Virus

Sung, Nancy S.; Pagano, Joseph S.

doi:10.1007/978-1-4899-1100-1_18

Cited by 2 publications

(6 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Much of the interest in the gammaherpesviruses comes from their association with cell proliferation and cancer. EBV may directly cause B lymphoproliferative disease in immune‐deficient humans and is an etiologic agent in Burkitt’s lymphoma, Hodgkin’s disease, unusual T‐cell lymphomas and nasopharyngeal carcinoma [83–86]. Besides infectious mononucleosis, EBV may also cause a variety of other neurological syndromes.…”

Section: Epstein–barr Virusmentioning

confidence: 99%

“…They comprise six Epstein–Barr nuclear antigens (EBNA1, 2, 3A, 3B, 3C and LP) and three integral membrane proteins (LMP1, 2A and 2B). In addition, two genes coding for small RNAs (EBER1 and EBER2) are actively transcribed in most latently EBV‐infected cells [85,91]. During the lytic cycle, however, most EBV genes are expressed.…”

Section: Epstein–barr Virusmentioning

confidence: 99%

“…The oncogenicity of EBV is mainly ascribed to EBNA2 [85] and LMP1 [189–190]. EBNA2 is the earliest EBV gene to be expressed after infection.…”

Section: Episomal Virus‐derived Vectors Ingene Therapymentioning

confidence: 99%

“…EBNA2 is the earliest EBV gene to be expressed after infection. The role of EBNA2 in latency and pathogenesis probably centers around its ability to activate both viral and cellular promoters [85]. EBNA1 has long been reported to possess no transformation activity.…”

Section: Episomal Virus‐derived Vectors Ingene Therapymentioning

confidence: 99%

“…In addition, Sung et al . [85] showed some functional similarities between the EBV oriP and the enhancer region near the c‐ myc gene, raising the possibility that, under particular circumstances, this sequence could also interact with EBNA1, resulting in deregulation of the proto‐oncogene c‐ myc . In vivo experiments also create doubts about the harmlessness of EBNA1.…”

Section: Episomal Virus‐derived Vectors Ingene Therapymentioning

confidence: 99%

See 4 more Smart Citations

Episomal vectors for gene expression in mammalian cells

Craenenbroeck¹,

Vanhoenacker²,

Haegeman³

2000

European Journal of Biochemistry

131

102

View full text Add to dashboard Cite

An important reason for preferring mammalian cells for heterologous gene expression is their ability to make authentic proteins containing post-translational modifications similar to those of the native protein. The development of expression systems for mammalian cells has been ongoing for several years, resulting in a wide variety of effective expression vectors. The aim of this review is to highlight episomal expression vectors. Such episomal plasmids are usually based on sequences from DNA viruses, such as BK virus, bovine papilloma virus 1 and Epstein±Barr virus. In this review we will mainly focus on the improvements made towards the usefulness of these systems for gene expression studies and gene therapy.

show abstract

Section: Epstein–barr Virusmentioning

confidence: 99%

Section: Epstein–barr Virusmentioning

confidence: 99%

“…The oncogenicity of EBV is mainly ascribed to EBNA2 [85] and LMP1 [189–190]. EBNA2 is the earliest EBV gene to be expressed after infection.…”

Section: Episomal Virus‐derived Vectors Ingene Therapymentioning

confidence: 99%

Section: Episomal Virus‐derived Vectors Ingene Therapymentioning

confidence: 99%

Section: Episomal Virus‐derived Vectors Ingene Therapymentioning

confidence: 99%

See 3 more Smart Citations

Episomal vectors for gene expression in mammalian cells

Craenenbroeck¹,

Vanhoenacker²,

Haegeman³

2000

European Journal of Biochemistry

131

102

View full text Add to dashboard Cite

show abstract

An episomal DNA vector platform for the persistent genetic modification of pluripotent stem cells and their differentiated progeny

et al. 2022

View full text Add to dashboard Cite

The genetic modification of stem cells (SCs) is typically achieved using integrating vectors, whose potential integrative genotoxicity and propensity for epigenetic silencing during differentiation limit their application. The genetic modification of cells should provide sustainable levels of transgene expression, without compromising the viability of a cell or its progeny. We developed nonviral, nonintegrating, and autonomously replicating minimally sized DNA nanovectors to persistently genetically modify SCs and their differentiated progeny without causing any molecular or genetic damage. These DNA vectors are capable of efficiently modifying murine and human pluripotent SCs with minimal impact and without differentiation-mediated transgene silencing or vector loss. We demonstrate that these vectors remain episomal and provide robust and sustained transgene expression during self-renewal and targeted differentiation of SCs both in vitro and in vivo through embryogenesis and differentiation into adult tissues, without damaging their phenotypic characteristics.

show abstract

Molecular Mechanisms of Transformation by Epstein-Barr Virus

Cited by 2 publications

References 164 publications

Episomal vectors for gene expression in mammalian cells

Episomal vectors for gene expression in mammalian cells

An episomal DNA vector platform for the persistent genetic modification of pluripotent stem cells and their differentiated progeny

Contact Info

Product

Resources

About